Targeting treatment options for castration-resistant prostate cancer

Area of Science:

• Oncology
• Urology
• Pharmacology

Background:

• Prostate cancer (PCa) is a leading cause of cancer death in men.
• Androgen-deprivation therapy (ADT) is standard for metastatic PCa but often leads to castration-resistant PCa (CRPCa).
• Existing treatments for CRPCa extend survival but do not offer a cure.

Purpose of the Study:

• To review recent advances in targeted therapy for prostate cancer.
• To discuss novel small molecules and therapeutic strategies for CRPCa.
• To highlight emerging vulnerabilities in PCa cells beyond androgen signaling.

Main Methods:

• Literature review of recent advancements in prostate cancer targeting therapy.
• Analysis of novel small molecules and their mechanisms of action.
• Discussion of emerging therapeutic strategies including immunotherapies and anti-angiogenesis agents.

Main Results:

• ADT resistance leads to lethal CRPCa.
• Targeting androgen signaling and docetaxel remain key, but new approaches are needed.
• Novel small molecules, immunotherapies, and anti-angiogenesis agents show promise.

Conclusions:

• Targeted therapies offer new hope for treating advanced prostate cancer.
• Exploiting PCa cell vulnerabilities is crucial for overcoming treatment resistance.
• Further research into novel small molecules and combination therapies is warranted for CRPCa.